<span id=Glen Barber">

Glen Barber

University of Miami Miller School of Medicine, USA

Dr. Barber is presently Chairman and Professor of the Department of Cell Biology at the University of Miami Miller School of Medicine (UMMSM), Miami, Florida, USA. He also holds the Eugenia J. Dodson Chair in Cancer Research at the UMMSM. Dr. Barber obtained his Ph.D from the Center for Applied Research and Microbiology (CAMR) and London University in 1989. After training at the University of Washington, Seattle, USA and the University of Tokyo, Japan, Dr. Barber became Assistant Professor at Emory University, Atlanta, USA in 1995.

Glen Barber">

View full bio

<span id=Rick Kennedy">

Rick Kennedy

Mayo Clinic, USA

Dr. Kennedy earned his B.S. degree in Microbiology from Brigham Young University and his Ph.D. in Immunology from Mayo Clinic with postdoctoral training in immunogenetics and vaccinology.

Rick Kennedy">

View full bio

<span id=Sanjay Phogat">

Sanjay Phogat


Since March 2019, responsible of the Discovery Performance Unit of the Italian Research & Development Center, leader in discovery and development of vaccines and human monoclonals.

Sanjay Phogat">

View full bio

<span id=Caroline Poland">

Caroline Poland

Poland Associates, USA

Caroline M. Poland is the Founder and President of Poland and Associates Consulting. She is a Licensed Mental Health Counselor, a Licensed Clinical Addictions Counselor, a Certified Clinical Trauma Professional, a Certified Compassion Fatigue Professional, and a Nationally Certified Counselor.

Caroline Poland">

View full bio

<span id=Noël Tordo">

Noël Tordo

Institut Pasteur de Guinée, Guinea/ Institut Pasteur, France

Noël Tordo">

View full bio

<span id=Kelli Warfield">

Kelli Warfield

Emergent Biosolutions, USA

Kelly Lyn Warfield, Ph.D. is the Vice President of Vaccines Research and Development at Emergent BioSolutions.  Dr. Warfield currently oversees a pipeline of vaccine candidates ranging from discovery through advanced development including recombinant viral vaccines, live attenuated bacterial vaccines, nanoparticle and virus-like particle (VLP) vaccines including the Phase 3 chikungunya VLP vaccine candidate.

Kelli Warfield">

View full bio

More speakers to follow...